Evidence map›Paper›PMID 40978504›Full record

ArticleFrontiers in drug safety and regulation2025

Implementing tokenization in clinical research to expand real-world insights.

Chelsea Walters, Crystal S Langlais, Eva E Oakkar, Wilhelmina E Hoogendoorn, James B Coutcher, Mui Van Zandt

Abstract read
In one paragraph

Article in Frontiers in drug safety and regulation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Chelsea WaltersReal World Solutions, IQVIA, Durham, NC, United States.
Crystal S Langlais *Real World Solutions, IQVIA, Durham, NC, United States.
Eva E Oakkar *Real World Solutions, IQVIA, Durham, NC, United States.
Wilhelmina E HoogendoornReal World Solutions, IQVIA, Durham, NC, United States.
James B CoutcherReal World Solutions, IQVIA, Durham, NC, United States.
Mui Van ZandtReal World Solutions, IQVIA, Durham, NC, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Interest in leveraging real-world data (RWD) to support clinical research is increasing, including studies to further characterize safety and effectiveness of new treatments. Such studies often require a combination of primary, study-specific data, with secondary, existing RWD. So-called enriched studies are becoming more common but require tailored methodologies that facilitate linkage across data sources. Tokenization has emerged as a key tool in the United States (US) to enable the linkage of secondary data with primary data, although key considerations to operationalize tokenization are often overlooked during study set-up. This article aims to explore key aspects for implementing tokenization in the US and to define relevant terminology. Appropriate study designs and RWD sources to leverage this tool are also discussed and advantages and considerations for study stakeholders to enhance possibilities to generate real-world evidence are highlighted. The article concludes with a description of case studies where tokenization is a suitable fit to fulfill study goals.

Indexed as

data linkagedata privacyde-identificationreal-world datareal-world evidencetokenization

Identifiers

PMID40978504
PMCPMC12443073

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.